Evidence for the prognostic value of TP53 mutations in circulating tumor DNA across solid malignancies: a systematic review and meta-analysis
Lan Jinyan, Liang Yibin, Qin Jiangkui, Huang Shanbo, Glenn Deng, Changsheng Sun, He Yongyu, Huang Gang, Yi Tingzhuang · 2026
Read Evidence for the prognostic value of TP53 mutations in circulating tumor DNA across solid malignancies: a systematic review and meta-analysis by Lan Jinyan, Liang Yibin, Qin Jiangkui, Huang Shanbo, Glenn Deng, Changsheng Sun, He Yongyu, Huang Gang, Yi Tingzhuang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13474983.txt.
Description
Lan and colleagues pooled studies in 2026 on whether TP53 mutations found in tumor DNA floating in the blood predict how cancer patients fare. This circulating tumor DNA, shed by cancers into the bloodstream, can be read from a simple blood draw. The team searched four databases through May 2025 and combined survival results from 21 studies covering 2,685 patients with the mutation.
Patients whose blood carried a TP53 mutation progressed sooner, with a pooled hazard ratio of 2.10 across 12 studies reporting that outcome. They also died sooner overall, at a hazard ratio of 1.74 across nine studies, and their disease-free survival was shorter in the three studies measuring it. Effects ran strongest in lung and liver cancers and weaker in breast cancer, and the authors call for standard test methods before clinics adopt the marker routinely.
Catalog record
| CREATOR | Lan Jinyan, Liang Yibin, Qin Jiangkui, Huang Shanbo, Glenn Deng, Changsheng Sun, He Yongyu, Huang Gang, Yi Tingzhuang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |